Dr. Greten on Promising Immunotherapy Agents in HCC

Tim F. Greten, MD
Published Online: Friday, May 19, 2017



Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).

The immunotherapy that is furthest developed in this space is nivolumab (Opdivo), which is being investigated in a phase III study, explains Greten.
,br> Additionally, cell-based therapies are being looked at but they are harder to investigate as there are very little data to analyze, states Greten.

Chimeric antigen receptor (CAR) T-cell therapy has not been very successful in solid cancers but it is 1 of the future areas that will be studied for patients with HCC.



Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).

The immunotherapy that is furthest developed in this space is nivolumab (Opdivo), which is being investigated in a phase III study, explains Greten.
,br> Additionally, cell-based therapies are being looked at but they are harder to investigate as there are very little data to analyze, states Greten.

Chimeric antigen receptor (CAR) T-cell therapy has not been very successful in solid cancers but it is 1 of the future areas that will be studied for patients with HCC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment and Management of CINVJul 26, 20171.5
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Genitourinary CancersJul 28, 20171.5
Publication Bottom Border
Border Publication
$emailPop$